A phase 3 trial of Johnson & Johnson's TAR-200 therapy in bladder cancer has failed to show efficacy, although the company is still confident in the potential of the programme. The SunRISe-2 study, in ...
Takeda has said it intends to move quickly ahead with regulatory filings for oveporexton, its orexin agonist for sleep disorder narcolepsy, after a clean sweep of positive efficacy data in two phase 3 ...
Radio 4's flagship news and current affairs programme; including religious reflections from Thought for the Day at 0748 News and current affairs, including Sports Desk, Weather and Thought for the Day ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback